The Chief Executive of the ABPI Executive Director, Dr Richard Torbett, has published a statement on medicines pricing and the impasse on access to Orkambi.
The statement offers a view on the landscape on medicines pricing in the UK, highlighting the impact of the Voluntary Scheme for Branded Medicines Pricing and Access (VPAS).
“Prices for new medicines need to offer value for money for the NHS. At the same time, they need to allow for ongoing research and development efforts that will produce more innovation for the future.
“These dual principles are enshrined in the Voluntary Scheme for Branded Medicines Pricing and Access (VPAS), which the industry and government jointly developed to govern how prices are set, and how NHS spend on branded medicines (which covers the vast majority of new medicines) is managed.”
The statement then reflects on NHS England’s recent letter to the Health and Social Care Select Committee. This letter discussed some of the underlying principles of NHS England’s most recent offer to Vertex on the 23rd of May, while not disclosing precise details of the pricing offer:
“In the case of Orkambi, NHS England’s recent letter to the Health and Social Care Select Committee, makes clear that it has offered a two year managed entry agreement with data collection that would secure patient access in the short term, while allowing the price to go up or down later depending on the evidence collected.
“Whilst we would reiterate that we don’t know any of the commercial details, i.e. the prices, involved in this offer, it is clear that the structure of the offer represents exactly the sort of flexibility industry has been calling for some time – and indeed responds to some of the observations made by the HSC Committee. It feels like a helpful step in the right direction and we certainly welcome that.”
Read the full statement here.